Friedenthal Financial Purchases New Stake in Elanco Animal Health Incorporated $ELAN

Friedenthal Financial purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 44,954 shares of the company’s stock, valued at approximately $1,076,000.

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. lifted its stake in shares of Elanco Animal Health by 1,436.1% in the first quarter. Blue Trust Inc. now owns 23,487 shares of the company’s stock valued at $562,000 after buying an additional 21,958 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in shares of Elanco Animal Health by 4.2% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock worth $342,000 after acquiring an additional 579 shares during the last quarter. OP Asset Management Ltd bought a new position in Elanco Animal Health in the 1st quarter valued at about $8,171,000. Corient Private Wealth LLC lifted its position in Elanco Animal Health by 35.6% in the 4th quarter. Corient Private Wealth LLC now owns 100,895 shares of the company’s stock valued at $2,283,000 after acquiring an additional 26,507 shares in the last quarter. Finally, Kera Capital Partners Inc. boosted its stake in Elanco Animal Health by 79.0% during the 4th quarter. Kera Capital Partners Inc. now owns 21,735 shares of the company’s stock valued at $523,000 after purchasing an additional 9,595 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

ELAN stock opened at $23.96 on Thursday. The firm has a market cap of $11.97 billion, a PE ratio of -47.91, a P/E/G ratio of 1.52 and a beta of 1.69. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The business has a 50 day moving average of $23.01 and a 200-day moving average of $23.53. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period last year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 1.1 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, KeyCorp increased their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $28.55.

Insider Transactions at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi bought 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.